Researchers at Mass General Brigham have developed a strategy to promote antitumor immunity by inducing cancer cells to produce an immune-activating molecule. This approach was shown to reduce tumor growth and improve survival in mouse models of aggressive melanoma, with potential applications beyond cancer therapies.
Researchers at Northwestern University have discovered how pancreatic tumors evade the immune system and created an antibody therapy that blocks this mechanism, reawakening immune cells to attack cancer cells. The study shows promise for treating pancreatic cancer and may have broader implications for other hard-to-treat cancers.
Researchers at Monash University have developed a new strategy to improve CAR T cell therapy for solid tumors. By targeting the PTPN2 protein, they enhanced the efficacy of CAR T cells and generated long-lived memory T cells that can persist in circulation.
A UCLA study finds that DNA copy-number changes enable melanoma cells to resist immune attacks, leading to tumor relapse. The researchers suggest a strategy to make tumors more prone to self-destruction after immune attacks, potentially extending the effectiveness of immunotherapy.
The Innovative Cancer Medicines (ICM) initiative, a collaboration between CHAI and PICI, has enrolled the first Nigerian patient in a demonstration project using an immunotherapy drug. The goal is to develop sustainable and effective administration of innovative immuno-oncology therapies in low- and middle-income countries.
The review highlights how T cells specifically recognize and eliminate malignant cells through antigen recognition mechanisms. It also explores how tumors evade immune surveillance through various mechanisms and discusses potential therapeutic strategies, including combination therapies to improve response rates for cancer patients.
UofL Health – Brown Cancer Center oncologists and researchers will continue developing novel therapies using patients' own immune system to defeat cancer. The center's faculty and research facilities support clinical trials that bring new treatments to patients.
A new blood-based liquid biopsy model, LiBIO score, predicts immunotherapy response with high accuracy. The model identifies an early post-treatment time point as optimal for assessing treatment response and can help identify patients who are more likely to benefit from immunotherapy.
Researchers at Tokyo University of Science identified genes that predict CD8+ T cell expansion in cancer immunotherapy. A 'signature gene set' or 'expansion signature' was found to identify primed T cells for growth, predicting treatment response and offering a potential guide for new therapies.
Researchers found that combining zanzalintinib, a targeted therapy drug, with atezolizumab, an immune checkpoint inhibitor, improved survival rates by 20% compared to standard treatment regorafenib. The new combination also delayed cancer progression and showed promising results in patients with metastatic colorectal cancer.
Researchers at NYU Langone Health found that pembrolizumab therapy results in a trend toward improvement in survival rates for patients with Merkel cell carcinoma. After two years, 73% of patients taking pembrolizumab showed no signs of cancer recurrence.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.
A new class of anti-cancer agents—antibody-drug conjugates (ADCs)—has unveiled compelling evidence that can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer. The phase III DESTINY-Breast05 and DESTINY-Breast11 trials have shown superior efficacy and improved disease-free survival rates, positionin...
Researchers developed a novel technology to attach 'fake targets' to tumor cells, enabling immune cells to attack regardless of antigen presence. The Univody platform showed promising results in animal models, suppressing tumor growth and triggering broader immune activation.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
A study found that higher thymic health is associated with better outcomes in cancer patients treated with immunotherapy, including a 35% lower risk of cancer progression and 44% lower risk of death. Thymic health may serve as a non-invasive biomarker of adaptive immune competence in various cancers.
The ESMO Congress 2025 will cover key topics including precision oncology, antibody-drug conjugates in breast cancer, dose optimisation strategies, new treatment modalities for melanoma, and immunotherapy-based approaches across various cancer settings. Promising Phase-3 studies on ADCs in bladder and lung cancer are also expected.
Researchers at UMass Amherst have developed a nanoparticle-based vaccine that prevents melanoma, pancreatic and triple-negative breast cancer in mice. The vaccine achieved remarkable survival rates, with up to 88% of vaccinated mice remaining tumor-free.
Researchers at UCSF have discovered a novel combination of immunotherapies that can reprogram the immune environment of colon cancer tumors in the liver. This therapy often eliminated tumors entirely in preclinical models, showing promise for treating patients with advanced colorectal cancer.
A new mRNA cancer vaccine platform has been developed using a hydrogel-based approach that actively recruits immune cells. This improves efficiency and leads to stronger antitumor immune responses in preclinical models. The research is still in its early stages, but it holds promise for future cancer treatments.
A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.
A new method has been developed to generate induced natural killer cells and CAR-engineered NK cells from cord blood-derived hematopoietic stem and progenitor cells. This approach increases the induction efficiency of NK cells and lowers the cost of CAR engineering, offering a promising avenue for cancer immunotherapy.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
The research team developed multifunctional nanocomposites that demonstrate excellent tumor-targeting capability through the EPR effect. Irradiation with near-infrared laser light achieved multidimensional therapeutic effects, including complete elimination of transplanted mouse cancers within 5 days.
Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.
Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.
Researchers developed a fusion protein that blocks the 'do not attack' signal and selectively activates tumor-fighting immune cells. The molecule, combining an IL-2 variant with a PD-1 antibody, induces a multifaceted anti-tumoral T cell response in human lung cancer patients.
Research has shown that lymph nodes provide the right environment for stem-like T cells to survive, multiply, and produce killer cells. Preserving lymph nodes could strengthen immune responses and increase the effectiveness of immunotherapy. The study's findings have important implications for cancer therapy.
The researchers developed a novel cell-surface protein engineering strategy called PATCH, which applies proximity labeling to immunomodulation for the first time. This approach directly amplifies targeting signals on the tumor cell surface, identifying cells that need to be attacked by the immune system.
UCSF researchers develop a new strategy to prime CAR T cell therapy by combining it with diabetes drugs, increasing the efficacy of NECTIN4-CAR T cells in treating urothelial carcinoma. The study shows that using thiazolidinediones enhances NECTIN4 expression, making tumor cells more susceptible to the treatment.
Researchers found that lung tumors reshape immune cells in the bone marrow before they reach the cancer, altering their function and leading to a stronger anti-cancer response. The study identified NRF2 as a key protein involved in this process and proposed blocking it as a potential strategy to enhance immunotherapy.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
DZ-002 is an innovative cancer treatment developed through a collaborative effort among Georgia State University, Emory University and Cedars-Sinai Medical Center. The technology harnesses targeted radiation to destroy tumors with precision, offering hope for improved patient outcomes.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
A study led by Yibin Kang and Yujiao Han reveals that cancer cells hijack a specialized cell to recycle iron, depriving red blood cells of necessary iron and causing anemia. The discovery aims to slow down bone metastasis and alleviate complications.
A team of scientists has developed a protein-based therapeutic tool called Crunch to target and remove specific living cells, such as cancer cells or overactive immune cells. The new system uses the body's natural waste removal system to clear out unwanted cells, offering hope for improved treatments.
A study published in Cell Reports Medicine found that zeaxanthin, a plant-derived carotenoid, strengthens the activity of immune cells that kill tumor cells. The findings suggest that zeaxanthin could complement and strengthen advanced cancer treatments like immunotherapy.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
Researchers at Purdue University have developed a new method to study biochemical processes that impair the immune system's ability to recognize and kill cancer cells. The method involves tracking RNA-binding proteins and extracellular vesicles, which can compromise immunotherapy.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...
In a phase 1 clinical trial, the engineered antibody improved a class of drugs that had struggled to deliver on its early promise. Six patients experienced systemic tumor reduction, including two complete responses, with minimal side effects.
A team of researchers has visualized the nanoscale architecture of CD20 receptors and their interactions with anti-CD20 antibodies using a novel super-resolution microscopy technique. The study reveals that structural changes in antibody design translate into different receptor patterns and cellular responses, opening up new pathways f...
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
Researchers at La Jolla Institute for Immunology examine how genetics, sex hormones, and environmental factors shape the immune system. Women have a stronger immune response due to their XX chromosomes and estrogen, but also face an increased risk of autoimmune diseases.
Research suggests that consuming high levels of sucralose can make cancer treatment less effective by disrupting the gut microbiome and altering T cell function. However, adding arginine or citrulline supplements to the diet may restore immunotherapy effectiveness in patients with melanoma and non-small cell lung cancer.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
A new study found that immunotherapy may change the bone marrow environment where cancer cells live, potentially helping the immune system respond more effectively. Researchers tracked how the immune system interacts with cancer cells after treatment and noticed changes in cellular neighborhoods and cell communication.
Researchers developed a new AI model named BATMAN to improve T cell receptor therapy accuracy. The AI uses a vast database of over 22,000 TCR-peptide interactions to predict peptide binding and identify potential cancer treatments.
Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.
A plant virus, cowpea mosaic virus (CPMV), has shown promise as a low-cost and potent cancer immunotherapy. CPMV stimulates type I, II, and III interferons, which have well-known anti-cancer properties, and activates toll-like receptor 7 to prime antiviral and anti-tumor immune responses.
A study published in Nature found that autoantibodies can tilt the odds dramatically toward shrinking tumors and enhance the effectiveness of immunotherapy. Certain autoantibodies linked to better clinical outcomes could reveal cancer's weak spots and point to new targets for treatment.
Researchers have discovered an experimental mRNA vaccine that can boost tumor-fighting effects of immunotherapy, sparking a new approach to battling many types of treatment-resistant tumors. The study found that pairing the test vaccine with common anticancer drugs triggered a strong antitumor response.
The inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025 will convene a diverse group of stakeholders to foster collaboration and accelerate the development of innovative cancer therapies. The congress aims to become a catalyst for global collaboration and innovation in oncology.
Researchers developed a biomimetic physical barrier that temporarily blocks T cell-tumor cell interactions, delaying exhaustion and enabling a stronger immune response. The breakthrough strategy can potentially be combined with other immunotherapeutic approaches to enhance treatment efficacy.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
Researchers developed a novel immunotherapy that disrupts the IL-33/IL1RL1 signaling loop to boost immune function and improve survival in leukemia patients. The treatment targeted leukemia stem cells, reducing relapse rates and improving survival without major side effects.
A new study from Uppsala University found that most men with prostate cancer who receive recommended treatment have a good prognosis, with a lower risk of dying from prostate cancer than other causes. The study's findings highlight the importance of assessing a patient's life expectancy in choosing an appropriate treatment strategy.